R

    Rezolute Inc (RZLT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.69
    +0.07 (+1.52%)

    Market Cap: $451.61M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(19/28)
    Avg Surprise
    +3.84%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.08
    Range$-0.11 - $-0.06
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.18 - $-0.12
    5 analysts
    EPS Revisions
    1
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$-0.16-10.8%
    60d ago$-0.15+0.0%
    30d ago$-0.15+0.0%
    7d ago$-0.15+0.0%
    Current$-0.15
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-0.15---
    Jun 26EST
    		-$-0.08---
    Mar 26
    Reported May 12
    		$-0.16$-0.17+7.99%Beat+42.4%
    Dec 25
    Reported Feb 12
    		$-0.22$-0.18-22.22%Miss+0.0%
    Sep 25
    Reported Nov 6
    		$-0.18$-0.26+30.77%Beat+18.2%
    Jun 25
    Reported Sep 17
    		$-0.26$-0.21-21.89%Miss+40.9%
    Mar 25
    Reported May 13
    		$-0.27$-0.24-12.50%Miss+20.6%
    Dec 24
    Reported Feb 12
    		$-0.22$-0.26+15.38%Beat+18.5%
    Sep 24
    Reported Nov 7
    		$-0.22$-0.34+35.29%Beat+21.4%
    Jun 24
    Reported Sep 19
    		$-0.44$-0.33-33.33%Miss-76.0%
    Mar 24
    Reported May 15
    		$-0.34$-0.32-6.25%Miss-13.3%
    Dec 23
    Reported Feb 13
    		$-0.27$-0.29+6.90%Beat-3.8%
    Sep 23
    Reported Nov 13
    		$-0.28$-0.28+0.00%Beat-47.4%
    Jun 23
    Reported Sep 14
    		$-0.25$-0.36+30.56%Beat+32.4%
    Mar 23
    Reported May 11
    		$-0.30$-0.30+0.00%Beat+53.8%
    Dec 22
    Reported Feb 10
    		$-0.26$-0.32+18.75%Beat+67.5%
    Sep 22
    Reported Nov 9
    		$-0.19$-0.35+45.71%Beat+79.3%
    Jun 22
    Reported Sep 15
    		$-0.37$-0.41+9.76%Beat+52.6%
    Mar 22
    Reported May 12
    		$-0.65$-0.97+32.99%Beat+1.5%
    Dec 21
    Reported Feb 9
    		$-0.80$-0.66-21.21%Miss+9.1%
    Sep 21
    Reported Nov 12
    		$-0.92$-0.89-3.37%Miss-48.4%
    Jun 21
    Reported Sep 15
    		$-0.78$-0.80+2.50%Beat-28.9%
    Mar 21
    Reported May 17
    		$-0.66$-0.78+15.38%Beat+34.0%
    Dec 20
    Reported Feb 10
    		$-0.88$-0.75-17.33%Miss+12.0%
    Sep 20
    Reported Oct 13
    		$-0.62$-0.84+26.19%Beat+38.0%
    Jun 20
    Reported Sep 2
    		$-0.60$-0.61+0.82%Beat+69.8%
    Mar 20
    Reported May 14
    		$-1.00$-1.00+0.00%Beat-212.5%
    Dec 19
    Reported Feb 12
    		$-1.00$-1.00+0.00%Beat-1328.6%
    Sep 19
    Reported Nov 14
    		$-1.00$-1.00+0.00%Beat-400.0%
    Jun 19
    Reported Sep 10
    		$-2.00$-1.50-33.33%Miss+81.0%
    Mar 19
    Reported May 10
    		$-0.32N/AN/ABeat-255.6%
    Dec 18
    Reported Feb 14
    		$-0.07N/AN/ABeat+34.2%
    Sep 18
    Reported Dec 14
    		$-0.20N/AN/ABeat-58.2%
    Jun 18
    Reported Jun 30
    		$-10.50N/AN/ABeat-7976.9%
    Mar 18
    Reported May 15
    		$-0.09N/AN/ABeat+99.1%
    Dec 17
    Reported Feb 14
    		$-0.11N/AN/ABeat+98.2%
    Sep 17
    Reported Nov 14
    		$-0.13N/AN/ABeat+97.7%
    Jun 17
    Reported Sep 22
    		$-0.13N/AN/ABeat-
    Mar 17
    Reported May 15
    		$-10.36N/AN/ABeat-
    Dec 16
    Reported Feb 2
    		$-5.99N/AN/ABeat-
    Sep 16
    Reported Nov 14
    		$-5.39N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-5.75EV/EBITDA-0.01x
    Price/FCF-6.64xFCF Yield-15.06%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-81.70%ROIC-58.66%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio15.84xQuick Ratio15.84x
    Trading Statistics
    Beta0.62Avg Volume1.42M
    52-Week High$11.4652-Week Low$1.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.85
    SMA 20$4.77
    SMA 50$4.85
    SMA 200$4.23
    EMA 10$4.82
    EMA 20$4.81
    EMA 50$4.67
    EMA 200$4.51

    MACD

    Line: 0.02Signal: 0.03Hist: -0.01

    ADX

    ADX: 20.1+DI: 25.4-DI: 18.3

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down56.0
    PSAR$4.58

    Bollinger Bands

    Upper Band$5.11
    Lower Band$4.43
    %B Position1428%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    46.8

    Momentum Oscillators

    Stoch %K27.1
    Stoch %D37.2
    Williams %R-79.1
    ROC (10d)0.2%
    Momentum0.01
    CCI (20d)-54.0
    MFI (14d)64.1

    Volatility Measures

    ATR (14d)$0.30(6.3%)
    StdDev (20d)0.17
    Hist Vol50.8%(High)

    Volume Flow

    VWAP$4.68
    OBV11.2M
    AD Line70.0M
    CMF (20d)-0.239

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.5x
    VWMA (20d)$4.86

    Pivot Points

    R3$5.22
    R2$5.09
    R1$4.85
    Pivot Point$4.72
    S1$4.48
    S2$4.35
    S3$4.11

    Advanced Oscillators

    TSI2.65
    Ultimate Osc44.1
    KST-3.44

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$0$46,000$0$0$0$58,000$0$0$0$0
    Cost of Revenue$0$0$0$8,000$0$0$0$7,000$0$0$0$128,000
    Gross Profit$0$0$0$-8,000$0$0$0$51,000$0$0$0$-128,000
    Operating Expenses$17.37M$24.22M$19.82M$25.85M$20.02M$17.08M$16.94M$23.10M$16.21M$15.19M$15.91M$14.24M
    R&D$11.41M$14.35M$13.15M$20.86M$15.28M$12.63M$12.75M$19.09M$12.40M$12.04M$12.21M$10.93M
    SG&A$5.95M$9.87M$6.67M$4.99M$4.74M$4.45M$4.19M$4.01M$3.81M$3.15M$3.70M$3.31M
    Operating Income$-17,366,000$-24,221,000$-19,817,000$-25,850,000$-20,023,000$-17,080,000$-16,941,000$-23,102,000$-16,213,000$-15,194,000$-15,914,000$-14,238,000
    Interest Income$1.20M$1.45M$1.68M$1.45M$1.11M$1.34M$1.58M$1.04M$1.12M$1.30M$1.40M$1.48M
    Interest Expense$0$0$0$0$0$0$0$0$837,000$0$0$0
    Income Before Tax$-16,171,000$-22,774,000$-18,150,000$-24,390,000$-18,914,000$-15,730,000$-15,378,000$-22,976,000$-17,050,000$-13,909,000$-14,524,000$-12,723,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-16,171,000$-22,774,000$-18,150,000$-24,390,000$-18,914,000$-15,730,000$-15,378,000$-22,976,000$-17,050,000$-13,909,000$-14,524,000$-12,728,000
    EBITDA$-17,839,000$-24,927,000$-20,623,000$-26,162,000$-20,524,000$-17,789,000$-17,782,000$-24,747,000$-19,082,000$-17,356,000$-14,945,000$-14,851,000
    EBIT$-17,366,000$-24,221,000$-19,832,000$-25,835,000$-20,029,000$-17,074,000$-16,956,000$-24,017,000$-18,172,000$-15,212,000$-15,928,000$-14,198,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RZLT

    News

    Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $6

    Wedbush has reiterated its Buy rating for Rezolute (RZLT.US) and maintained its target price at $6. This indicates continued confidence from Wedbush in the company's prospects and valuation.

    Moomoo•8/25/26•
    Bullish

    Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit

    Rezolute, Inc. (NASDAQ:RZLT), a late-stage rare disease company, is projected to reach profitability by 2029, according to analysts. The company, which currently has a market capitalization of US$532m and reported a US$81m trailing-twelve-month loss, is expected to grow at an aggressive annual rate of 56% to achieve this breakeven point. Notably, Rezolute operates without debt, reducing investment risk.

    Sahm•8/22/26•
    Bullish

    Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit

    Rezolute, Inc. (NASDAQ:RZLT), a late-stage rare disease company, is projected by analysts to achieve profitability by 2029, moving from a current loss of US$81m to an anticipated US$66m profit. This transition requires an optimistic annual growth rate of 56%. A notable aspect of Rezolute is its debt-free balance sheet, which reduces investment risk for the loss-making biotech.

    Simply Wall Street•8/22/26•
    Somewhat-Bullish

    RZLT Edges Higher As Traders Focus On Cash Runway And Volatility

    Rezolute Inc. (RZLT) stock increased by 10.73% due to optimism from its latest clinical trial progress, attracting active trading and high volatility. Despite being in a pre-profit phase with substantial cash burn, the company maintains a strong liquidity position with $120.2M in cash, providing a significant operating runway. Traders are focusing on technical breakouts around $4.70 and the company's strong balance sheet, with analysts projecting a 6-12 month target of $7 based on clinical data progression.

    Timothy Sykes•8/22/26•
    Somewhat-Bullish

    Rezolute Gains 11%, Insider Trades Reap Benefit

    Rezolute Inc. (NASDAQ: RZLT) saw its stock price jump by 11% today, indicating positive market sentiment. This increase follows recent insider trading activity, where insiders purchased a significant amount of shares, suggesting confidence in the company's future prospects. The article implies a correlation between the insider purchases and the recent stock appreciation.

    Moomoo•8/21/26•
    Bullish

    Frequently Asked Questions About RZLT

    Does RZLT pay dividends?
    Rezolute Inc (RZLT) does not currently pay a regular dividend.
    What is RZLT's market cap?
    Rezolute Inc (RZLT) has a market capitalization of $451.61M with a current stock price of $4.69.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In